9hon MSN
Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is a trending stock: Facts to know before betting on it
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
These five quality stocks come with at least a 6% dividend and are likely to raise their dividends year in and year out.
Among U.S.-listed healthcare stocks with market caps of at least $200 million, the three highest-yielding are Perrigo ( PRGO ...
It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that ...
If a monthly high dose can drive higher weight loss with a side effect profile that keeps patients on the medication, "Pfizer ...
Bristol Myers Squibb on Thursday delivered strong fourth quarter results — and better yet, issued a 2026 forecast that was ...
$2.90 per share would value Pfizer stock at less than 9 times earnings, Pfizer pays a 6.5% dividend yield -- and hasn't cut ...
The U.S. stock market sank after a mixed day of trading. The S&P 500 fell 0.8% Tuesday. The Dow Jones Industrial Average ...
The pharmaceutical giant (PFE) said two doses from a Phase 2b study of the once-a-month injection demonstrated weight reduction of 10% and 12.3% after 28 weeks in adults with obesity or overweight ...
Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.
Pfizer Inc. (NYSE:PFE) ranks among the stocks with the lowest forward PE ratios. On January 23, Goldman Sachs reaffirmed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results